CHS could slow pace of divestitures as it makes progress paying debt
Community Health Systems (CHS) plans to decelerate its hospital divestitures after making significant progress in debt reduction and improving cash flow. Since 2019, CHS has divested 35% of its hospital portfolio, paying down $1.1 billion in debt last year. Although early-phase discussions for some divestitures are ongoing, the company will now be more opportunistic, focusing on growth in core markets and expecting adjusted EBITDA between $1.3 billion and $1.5 billion for the current year.
Skandinaviska Enskilda Banken AB publ Sells 4,649 Shares of Labcorp Holdings Inc. $LH
Skandinaviska Enskilda Banken AB publ reduced its stake in Labcorp Holdings Inc. by 17.2%, selling 4,649 shares and retaining 22,458 shares worth $6.45 million. Despite this, other institutions significantly increased their holdings, with 95.94% of Labcorp stock owned by institutional investors. Labcorp reported strong financial results, beating EPS expectations, providing positive FY 2026 guidance, and declaring a quarterly dividend, though recent insider sales by the CEO and EVP were noted.
Labcorp Holdings Inc. $LH Shares Bought by Persistent Asset Partners Ltd
Persistent Asset Partners Ltd increased its stake in Labcorp Holdings Inc. (NYSE:LH) by 90% in the third quarter, making Labcorp its 11th largest holding. Several other institutional investors also adjusted their positions in the medical research company. Labcorp recently announced a quarterly dividend and reported Q4 earnings that topped analyst estimates, alongside insider share sales by EVP Jonathan C. Meltzer and CEO Adam H. Schechter.
JPMorgan Chase & Co. Has $308.32 Million Holdings in Labcorp Holdings Inc. $LH
JPMorgan Chase & Co. reduced its stake in Labcorp Holdings Inc. by 17.6% to 1,074,041 shares, valued at $308.32 million, during Q3 2025. Despite the reduction in holdings, JPMorgan raised its price target for Labcorp to $330 and maintained an "overweight" rating. Labcorp exceeded Q4 2025 EPS estimates with $4.07, and set strong FY2026 EPS guidance, although revenue slightly missed expectations.
Labcorp Holdings Inc. stock outperforms competitors on strong trading day
Labcorp Holdings Inc. (LH) shares rose 1.33% to $282.48 on Thursday, marking its second consecutive day of gains. The stock's performance stood out during a generally negative trading session for the broader market, as both the S&P 500 and Dow Jones Industrial Average recorded losses.
Is FDA and Reimbursement Momentum Altering The Investment Case For Guardant Health (GH)?
Guardant Health (GH) recently reported strong quarterly revenue, exceeding analyst expectations, driven by progress in FDA submissions, reimbursement expansion, and margin improvement. While the company faces ongoing concerns about profitability and cash burn, these developments suggest positive operational momentum. The investment narrative hinges on liquid biopsy becoming a large cancer testing franchise, with regulatory and payer traction being key catalysts for future growth and reduced equity financing risk.
Labcorp Holdings Inc. $LH Shares Sold by Vanguard Group Inc.
Vanguard Group Inc. reduced its stake in Labcorp Holdings Inc. by 0.7% in Q3, now owning 11.84% of the company worth $2.82 billion. Despite various other institutional investors increasing their holdings, several analysts maintain a "buy" rating, forecasting growth and setting a "Moderate Buy" consensus with an average target price of $302.75. Labcorp recently announced a quarterly dividend and reported Q4 EPS of $4.07, topping estimates, though revenue for the quarter slightly missed expectations.
Aberdeen Group plc Sells 6,077 Shares of Labcorp Holdings Inc. $LH
Aberdeen Group plc reduced its stake in Labcorp Holdings Inc. by 8.1%, selling 6,077 shares and now owning 68,544 shares valued at $19.38 million. This comes as Labcorp beat Q4 EPS expectations but slightly missed revenue, issued positive FY-2026 guidance, and received several analyst price target increases, leading to a "Moderate Buy" consensus. Additionally, CEO Adam H. Schechter sold 5,273 shares, and the company declared a quarterly dividend of $0.72 per share.
Alzheimer’s Test Launch And 2026 Outlook Might Change The Case For Investing In Labcorp (LH)
Labcorp (LH) recently reported strong Q4 2025 results, with higher sales and earnings, and issued positive 2026 revenue guidance. The company also launched an FDA-cleared Alzheimer's blood test, Elecsys pTau-181, which is expected to support its push into higher-value diagnostics. These developments, along with its share repurchase program, could significantly impact its long-term investment narrative and growth potential, though competitive pressures and reimbursement risks remain.
Labcorp's Narrow Economic Moat Remains Strong, in Our View
The article discusses Labcorp's strong narrow economic moat, highlighting its position in the diagnostic laboratory market. It notes favorable prospects due to healthcare payment model reforms, reprieves from PAMA cuts, and potential M&A opportunities. Author Debbie S. Wang also anticipates solid demand in 2025 leading to a strong start in 2026 for Labcorp.
Labcorp Hldgs (LH) Target Price Raised by Baird to $326 | LH Sto
Baird has raised its target price for Labcorp Holdings (LH) to $326 from $313, while maintaining an "Outperform" rating, indicating continued positive sentiment. This adjustment follows several other analysts who have also adjusted their ratings and price targets for Labcorp in recent months. Labcorp, one of the largest independent clinical laboratories in the U.S., offers a wide range of clinical lab tests.
Labcorp (NYSE:LH) Price Target Raised to $326.00
Robert W. Baird has raised its price target for Labcorp (NYSE:LH) to $326.00, reiterating an "outperform" rating, indicating a potential 17.9% upside. This adjustment follows mixed Q4 results where adjusted EPS beat expectations but revenue missed, and insider selling was noted despite high institutional ownership. Several other firms have also recently updated their ratings and price targets for Labcorp.
Labcorp Holdings Inc. (NYSE:LH) Q4 2025 Earnings Call Transcript
Labcorp Holdings Inc. (NYSE:LH) reported its Q4 and full-year 2025 earnings, announcing strong growth with over 7% top-line growth and 13% adjusted EPS growth for the year. The company provided an optimistic outlook for 2026, projecting approximately 9% adjusted EPS growth at the midpoint of its guidance, driven by strategic priorities such as deepening partnerships with health systems, advancing leadership in specialty testing, and leveraging technology and AI-powered solutions. Labcorp also addressed the delay of PAMA implementation and discussed its capital allocation strategy, including acquisitions and shareholder returns.
JPMorgan Adjusts Price Target on Labcorp Holdings to $330 From $319, Maintains Overweight Rating
JPMorgan has raised its price target for Labcorp Holdings (NYSE:LH) to $330 from $319, while maintaining an "Overweight" rating on the stock. This adjustment comes shortly after Labcorp reported its Q4 2025 results and provided guidance for 2026, which included upbeat annual profit forecasts driven by strong diagnostic product demand. The company also announced its Q4 adjusted earnings and revenue increases, alongside the launch of an FDA-cleared Alzheimer's blood test.
DNA RNA Banking Services Market Is Going to Boom | Thermo Fisher Scientific • Illumina • 23andMe • AncestryDNA
This report by Coherent Market Insights analyzes the DNA RNA Banking Services Market, predicting substantial growth from 2026 to 2033 due to rising demand and innovation. It covers key market trends, drivers, competitive landscape, and strategic opportunities for industry leaders, identifying major players like Thermo Fisher Scientific and Illumina. The study utilizes analytical tools like SWOT analysis and Porter's Five Forces to provide comprehensive insights and forecasts for various segments and regions.
Labcorp Holdings Inc. (NYSE:LH) Given Average Recommendation of "Moderate Buy" by Brokerages
Labcorp Holdings Inc. (NYSE:LH) has received a consensus "Moderate Buy" rating from thirteen brokerages, with an average one-year price objective of $300.75. The company recently reported Q4 adjusted EPS that beat estimates, along with positive FY2026 guidance, though revenue missed expectations and insider selling occurred. Despite some negative sentiment regarding revenue and insider activity, institutional investors have shown increased interest, and the stock exhibits solid financial performance metrics.
Labcorp Holdings (LH) Margin Improvement Reinforces Bullish Earnings Recovery Narrative
Labcorp Holdings (LH) achieved significant margin improvement in FY 2025, with revenue reaching US$3,515.8 million in Q4 and trailing twelve-month EPS at US$10.53, leading to a 6.3% net profit margin. This rebound in earnings follows a five-year decline, fueling a bullish narrative supported by new tests, efficiency gains, and recent acquisitions. However, skeptics point to a P/E ratio above the industry average, a high debt load, and modest revenue growth, suggesting execution risk remains.
Labcorp outlines 5.4% midpoint revenue growth and 9% EPS target for 2026 while advancing specialty and AI initiatives
Labcorp (NYSE: LH) has set ambitious financial targets for 2026, aiming for a 5.4% midpoint revenue growth and a 9% diluted EPS growth, with a focus on expanding its specialty testing and early development businesses. The company plans to achieve these goals through strategic investments in high-growth areas, advanced technology, and artificial intelligence, expecting to generate approximately $3.5 billion in free cash flow. Labcorp also outlined a capital allocation strategy that includes share repurchases, dividends, and M&A activities, projecting over $15 billion in capital deployment by 2028.
Why Labcorp (LH) Shares Are Trading Lower Today
Labcorp (LH) shares fell 2.7% after the company reported fourth-quarter revenue of $3.52 billion, which missed Wall Street's expectations of $3.57 billion, despite an earnings beat of $4.07 adjusted EPS. Although the company provided a solid full-year 2026 outlook, the revenue miss overshadowed the positive financial results, leading to the stock's decline. Labcorp's shares have shown relatively low volatility, making today's significant move noteworthy.
Why Labcorp (LH) Shares Are Trading Lower Today
Labcorp (LH) shares fell 2.7% after the company reported fourth-quarter revenue that missed Wall Street expectations, despite an earnings beat. While revenue grew 5.6% year-over-year, the Q4 figure of $3.52 billion was below the $3.57 billion forecast. The market's focus on this revenue miss led to the stock's decline, even though adjusted EPS and full-year 2026 guidance were positive.
Labcorp Q4 Earnings Beat, Revenues Miss, Stock Down in Pre-Market
Labcorp (LH) reported Q4 2025 adjusted earnings per share of $4.07, surpassing the Zacks Consensus Estimate by 3% and rising 18% year-over-year. However, revenues of $3.52 billion missed estimates by 1%, causing the stock to decline slightly in pre-market trading. The company also provided its full-year 2026 revenue and adjusted EPS guidance, with both metrics aligning closely with Zacks Consensus Estimates.
Earnings Summary – Labcorp Reports Fourth Quarter and Full Year 2025 Results and Issues 2026 Guidance
Labcorp (NYSE: LH) has reported strong financial results for the fourth quarter and full year 2025, showing revenue growth and improved earnings driven by its diagnostics operations. The company also provided optimistic guidance for full-year 2026, projecting continued revenue and adjusted EPS growth. Key initiatives included strategic acquisitions, significant investments in new facilities, and the launch of over 130 new tests.
Labcorp tops Q4 profit forecasts but revenue slightly misses
Labcorp reported better-than-expected fourth-quarter profits, driven by growth in its biopharma and diagnostics businesses. However, the company's revenue for the quarter slightly missed analysts' estimates. Labcorp also provided a full-year profit forecast that fell below Wall Street expectations, despite projecting organic revenue growth.
Labcorp forecasts upbeat annual profit on strong demand for diagnostic products
Labcorp (LH.N) has projected an upbeat annual profit, surpassing Wall Street estimates, driven by strong demand for its diagnostic tests and services. The company expects its diagnostic segment to grow between 5% and 6% in 2026, anticipating an annual adjusted profit per share of $17.55 to $18.25. This positive outlook is supported by steady demand for non-urgent surgeries and successful agreements to manage hospital laboratories.
New Waters microflow columns use 75% less sample in drug R&D
Waters Corporation has launched new 1 mm I.D. microflow LC columns with MaxPeak Premier Technology, designed for ACQUITY, BioResolve, and GTxResolve brands. These columns offer up to twice the sensitivity, use 75% less sample, and reduce solvent consumption by up to four times compared to 2.1 mm I.D. columns. This innovation aims to address challenges in bioanalysis, pharmaceutical development, and 'omics applications by improving recovery for various molecules while conserving precious resources.
Labcorp: Q4 Earnings Snapshot
Labcorp (LH) reported a fourth-quarter profit of $164.7 million, or $1.98 per share, with adjusted earnings of $4.07 per share which surpassed Wall Street expectations. However, the medical laboratory operator's revenue of $3.52 billion in the period fell short of forecasts. For the full year, Labcorp posted a profit of $876.5 million and revenue of $13.95 billion, and provided a positive outlook for full-year earnings and revenue.
Labcorp (NYSE:LH) Announces Quarterly Earnings Results
Labcorp (NYSE:LH) exceeded earnings expectations for the recent quarter, reporting $4.07 EPS against a consensus of $3.95, though revenue was slightly below estimates at $3.52 billion. The company also declared a quarterly dividend of $0.72 per share and saw insider selling from its EVP and CEO. Institutional investors hold a significant portion of the company's stock, and analysts maintain a "Moderate Buy" consensus rating for LH.
Labcorp Holdings earnings beat by $0.14, revenue fell short of estimates
Labcorp Holdings (NYSE: LH) reported fourth-quarter EPS of $4.07, exceeding analyst estimates by $0.14, though revenue of $3.52B fell short of the $3.56B consensus. The company provided fiscal year 2026 EPS guidance of $17.55-$18.25, aligning with analyst expectations. Labcorp's stock has seen positive performance, rising 6.40% in the last three months and 14.75% over the past year, with a "great performance" financial health rating from InvestingPro.
Labcorp 2025 Fourth Quarter and Full Year Results
Labcorp (LH) has released its financial results for the fourth quarter and full year ending December 31, 2025, showing strong performance with increased revenue and adjusted EPS. The company also provided optimistic guidance for 2026, driven by strategic initiatives, expanded partnerships, and new test launches.
Labcorp (NYSE:LH) Misses Q4 CY2025 Sales Expectations
Labcorp (NYSE:LH) reported Q4 CY2025 sales of $3.52 billion, falling short of analyst expectations, though revenue rose 5.6% year-on-year. Despite the sales miss, the company's adjusted EPS of $4.07 beat consensus estimates by 3.2%, and its full-year 2026 adjusted EPS guidance also exceeded analyst predictions. Although organic revenue growth was modest, Labcorp's CEO highlighted strong performance in its Diagnostics and Central Laboratory businesses for 2025.
Labcorp (NYSE:LH) Misses Q4 CY2025 Sales Expectations
Labcorp (NYSE:LH) reported its Q4 CY2025 earnings, missing revenue expectations at $3.52 billion but exceeding adjusted EPS estimates with $4.07 per share. While the company's full-year outlook for 2026 revenue is near analyst estimates, its long-term revenue growth has been inconsistent, although recent two-year organic growth shows improvement. Operating margins are up year-on-year, but five-year EPS growth has declined.
Mondrian Investment Partners LTD Invests $75.21 Million in Labcorp Holdings Inc. $LH
Mondrian Investment Partners LTD has acquired a new stake in Labcorp Holdings Inc. (NYSE:LH), purchasing 261,994 shares valued at approximately $75.21 million. Labcorp also recently declared a quarterly dividend of $0.72 per share, yielding 1.0% with an ex-dividend date of February 27th. Analysts currently maintain a "Moderate Buy" rating on Labcorp with a consensus price target of $300.75, while insiders have recently sold shares.
Labcorp: Q4 Earnings Snapshot
Labcorp Holdings Inc. reported a fourth-quarter profit of $164.7 million, or $1.98 per share, with adjusted earnings of $4.07 per share, surpassing analyst expectations. Despite beating profit estimates, the medical laboratory operator's revenue of $3.52 billion for the quarter fell short of Wall Street forecasts. For the full year, Labcorp's profit was $876.5 million on revenue of $13.95 billion, and the company provided a positive outlook for full-year earnings and revenue.
Labcorp: Q4 Earnings Snapshot
Labcorp (LH) reported Q4 profits of $164.7 million, or $1.98 per share, with adjusted earnings of $4.07 per share, surpassing analyst expectations. However, revenue for the quarter was $3.52 billion, falling short of Street forecasts. The company provided full-year earnings guidance between $17.55 and $18.25 per share, with revenue projected from $14.61 billion to $14.79 billion.
A Look At Guardant Health (GH) Valuation After Insider Selling And New Cancer Testing Updates
Guardant Health (GH) is under scrutiny following insider selling and new clinical data for its cancer testing products. Despite strong longer-term stock performance, recent insider activity and a high price-to-sales ratio raise questions about its current valuation. The company is considered 16.3% undervalued by Simply Wall St's primary narrative, but risks like high cash burn and legal uncertainty persist.
Labcorp (LH) To Report Earnings Tomorrow: Here Is What To Expect
Labcorp (LH) is set to announce its earnings results on Tuesday before market hours. Analysts anticipate a 7.2% year-on-year revenue growth to $3.57 billion and adjusted earnings of $3.94 per share. The company has generally met or exceeded revenue estimates in the past, and its stock has recently outperformed its peers in the healthcare providers & services segment.
Labcorp (LH) To Report Earnings Tomorrow: Here Is What To Expect
Labcorp (LH) is set to report its earnings tomorrow before market hours. Analysts expect the company's revenue to grow 7.2% year-on-year to $3.57 billion, with adjusted earnings anticipated at $3.94 per share. While the healthcare providers & services segment has generally underperformed, Labcorp's shares are up 4.2% over the last month and it heads into earnings with an average analyst price target higher than its current share price.
Is Labcorp Holdings (LH) Pricing Reflect Its Role In U.S. Diagnostics Today
Labcorp Holdings (LH) is analyzed for its current valuation using Discounted Cash Flow (DCF) and Price-to-Earnings (P/E) ratio methods. The DCF model suggests the stock is significantly undervalued by 52.5% at an estimated intrinsic value of $594.48 per share compared to its recent price of $282.63. Its P/E ratio of 27.40x is below Simply Wall St's proprietary Fair Ratio of 29.98x, further indicating potential undervaluation.
Labcorp EVP Meltzer sells $25,266 in stock By Investing.com
Labcorp EVP Jonathan C. Meltzer sold 87 shares of company stock for $25,266 and also disposed of 70 shares to cover tax obligations. The company, currently trading near its 52-week high, has a strong financial standing with a Piotroski Score of 9 and is set to report earnings soon. Labcorp has also expanded its cancer detection portfolio and made changes to its board of directors.
Guardant Health Grant Program Links Shield Test Access To Growth Story
Guardant Health has launched a Community Colorectal Cancer Screening Grant Program, offering free access to its FDA-approved Shield blood test in underserved communities. This initiative links public health goals with the company's strong stock performance, which has seen significant returns over the past three years. For investors, the program offers insight into the real-world adoption and patient reach of Guardant Health's product, though the company currently faces negative shareholders' equity and unprofitability.
Insider Selling: Labcorp (NYSE:LH) EVP Sells 87 Shares of Stock
Labcorp EVP Jonathan Meltzer sold 87 shares of the company's stock on February 12th for a total value of $25,266.54, reducing his stake by 3.03%. The company also declared a quarterly dividend of $0.72 per share, yielding approximately 1.0%. Analysts currently have a "Moderate Buy" consensus rating for Labcorp with an average target price of $300.75.
Labcorp (LH) CEO Schechter sells $1.49 million in stock By Investing.com
Labcorp CEO Adam H. Schechter sold 5,273 shares of common stock for $1.49 million and exercised 3,656 Restricted Stock Units, while also disposing of 1,521 shares for tax withholding. These transactions leave him with direct ownership of 89,478 Labcorp shares. The company has also expanded its molecular residual disease testing, declared a quarterly cash dividend, appointed new board members, and sold its Early Development medical device testing business to NAMSA.
Labcorp EVP Meltzer sells $25,266 in stock
Jonathan C. Meltzer, EVP of Operations at Labcorp, sold 87 shares of common stock for $25,266 on February 12, 2026, and an additional 70 shares for tax obligations on February 11, 2026. Despite these sales, Labcorp's stock is trading near its 52-week high, with an InvestingPro "Fair Value" assessment and a Piotroski Score of 9, indicating strong financial health. The company is set to report earnings on February 17, 2026, and has recently expanded its cancer testing portfolio and made changes to its Board of Directors.
OPCH Stock Price, Forecast & Analysis | OPTION CARE HEALTH INC (NASDAQ:OPCH)
This article provides an analysis of OPTION CARE HEALTH INC (OPCH) stock, detailing its current price, technical and fundamental ratings, and market performance. It includes key statistics, financial highlights, analyst forecasts predicting a 14.67% price increase, and information about its competitors and company profile.
Onconetix to Acquire Humanoid Robot Subsidiary of Realbotix
Onconetix, Inc. (Nasdaq: ONCO) has entered into a definitive agreement to acquire Realbotix, LLC, a humanoid robotics subsidiary of Realbotix Corp., in an all-stock transaction. Upon closing, Realbotix Parent is expected to own 75% to 90% of the combined company's fully diluted shares, and Realbotix Corp. CEO, Andrew Kiguel, will become the CEO of the combined entity. The acquisition will allow Onconetix to pivot its strategic direction into the AI-powered humanoid robotics sector, leveraging Realbotix's patented technologies for commercial applications in healthcare, hospitality, and customer service.
Charles River Labs Quarterly Resilience Faces Declining Organic Revenue Test
Charles River Laboratories (NYSE:CRL) reported resilient quarterly results despite a 2.3% average annual decline in organic revenue over the past two years, leading to a recent stock pullback. Analysts anticipate modest revenue growth and lower return on invested capital, suggesting the company relies more on cost control and execution than volume growth. Investors should monitor the company's efforts to rebuild its project pipeline and improve its return on invested capital given the current market sentiment and share price volatility.
A Look At Labcorp Holdings (LH) Valuation After Recent Share Price Pullback
Labcorp Holdings (LH) has experienced mixed short-term stock returns but shows double-digit gains over the last year, closing recently at $278.11. Despite a recent 4.06% one-day dip, the stock achieved a 9.50% return over 30 days and a 14.83% total shareholder return over a year. The company is considered undervalued with a fair value around $300.06, driven by anticipated growth from innovative tests and operational efficiencies from AI, though potential reimbursement cuts pose risks.
Mall greeters and TV guests: Realbotix robots to reshape Onconetix strategy
Onconetix (Nasdaq: ONCO) is acquiring Realbotix LLC, an AI-powered humanoid robotics company, in an all-stock transaction. This strategic pivot will shift Onconetix from its oncology focus to humanoid robotics, with Realbotix Parent expected to own 75-90% of the combined entity and Andrew Kiguel becoming the CEO. The deal, targeted for closure in the second half of 2026, requires shareholder and regulatory approvals.
How Does Charles River Laboratories International Stock Compare With Peers?
Charles River Laboratories International (CRL) stock saw a 7% return over the past year, but a deeper analysis reveals negative LTM revenue growth and a challenging negative P/E, suggesting headwinds despite respectable operating and free cash flow margins. CRL's operating margin, revenue decline, and -97.8 PE ratio lag behind peers due to factors like biopharma spending weakness and contract losses. The article compares CRL's growth, margin, and valuation against key competitors like LabCorp (LH), Thermo Fisher Scientific (TMO), IQVIA (IQV), Fortrea Holdings (FTRE), and Medpace Holdings (MEDP).
Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care
Labcorp has launched the Elecsys® pTau-181 test, the first and only FDA-cleared blood test for initial Alzheimer's disease assessment in primary care settings. This test, now available nationwide, helps clinicians rule out Alzheimer's in symptomatic patients aged 55 and older with 97.9% negative predictive value. It offers a less invasive alternative to traditional diagnostic methods, expanding Labcorp's comprehensive Alzheimer's blood test portfolio and supporting earlier assessment.
